Who Owns SD BioSensor Company?

SD BioSensor Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns SD BioSensor?

Unraveling the SD BioSensor SWOT Analysis is just the beginning; understanding its ownership is key to grasping its market power. The global diagnostics landscape is constantly evolving, and SD BioSensor, a leader in in-vitro diagnostics, is at the forefront. Knowing who controls this influential company provides critical insights for investors and industry watchers alike.

Delving into the SD BioSensor ownership structure reveals more than just financial stakes; it illuminates the strategic vision driving the SD BioSensor company. From its founding to its current status, the evolution of Who owns SD BioSensor offers a fascinating look at its journey. Understanding the interplay between SD BioSensor shareholders and management is crucial for anyone evaluating its future. This analysis will cover the SD BioSensor parent company, major stakeholders, and any significant shifts in ownership over time.

The SD BioSensor company was established in 2010. The specifics of the founding ownership and the exact equity distribution among the founders aren't available in public financial documents or press releases. This information is typically considered proprietary.

Details about the early investors, such as angel investors or friends and family who acquired shares during the initial phase, are usually part of a company's early funding rounds. However, specific details for SD BioSensor's early days are not widely publicized. Early ownership agreements, including vesting schedules or buy-sell clauses, would have been critical in shaping early ownership and control.

The initial ownership structure of SD BioSensor is not publicly available. Any early disputes or buyouts would have significantly influenced the early distribution of control within the company. Information on the founders and their initial shareholding percentages is not explicitly disclosed in general public information.

Key Points on SD BioSensor's Founding

While the precise details of the initial ownership structure of SD BioSensor remain undisclosed, the company's founding in 2010 signifies a foundational team with a shared vision. Early funding rounds often involve angel investors and other initial backers. The absence of public information on the founders and their initial equity stakes is common for privately held companies.

• SD BioSensor was founded in 2010, setting the stage for its growth in the in-vitro diagnostics sector.
• The specific equity split among the founders is not publicly available.
• Early investors, such as angel investors, often play a crucial role in the initial funding phases.
• Initial ownership agreements would have been key in determining early control and the company's trajectory.

SD BioSensor SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of SD BioSensor has transformed considerably since its inception. A pivotal moment was the initial public offering (IPO) on the Korea Exchange (KRX) under the ticker symbol 137310 in 2021. This event enabled the company to secure capital and offered liquidity to its early investors and founders. Understanding the evolution of SD BioSensor ownership is crucial for investors and stakeholders alike.

As of early 2025, the major stakeholders typically include the founding team, institutional investors, and public shareholders. Although specific percentages for individual institutional investors fluctuate, large investment funds and asset management companies generally hold a significant portion of the company's shares. For example, institutional investors collectively held a substantial portion of the company's shares as of March 2024. The acquisition of Meridian Bioscience in 2022 for approximately $1.53 billion also impacted the financial structure and ownership landscape of the SD BioSensor company, often involving new equity or debt financing.

The 2022 acquisition of Meridian Bioscience significantly broadened the company's global presence and diversified its product offerings. This strategic use of capital can influence shareholder value and future investment. For more insights into the SD BioSensor's strategic direction, consider reading about the Growth Strategy of SD BioSensor.

Key Takeaways on SD BioSensor Ownership

Understanding the ownership structure of SD BioSensor is essential for investors.

• The IPO in 2021 was a major turning point, changing the ownership dynamics.
• Institutional investors are key players, holding a significant portion of shares.
• Acquisitions, like Meridian Bioscience, reshape the financial structure and shareholder base.
• Keep an eye on the SD BioSensor shareholders and their evolving stakes.

SD BioSensor PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors of SD BioSensor oversees the company's strategic direction and ensures good corporate governance. The board typically includes a mix of executive directors, who are part of the company's management team, and independent directors, who provide external perspectives. The specific composition of the board, including the names and affiliations of the directors, is detailed in the company's annual reports and regulatory filings. These reports also outline any changes in board membership.

The board's role is crucial in representing the interests of SD BioSensor's shareholders. They are responsible for making key decisions, monitoring the company's performance, and ensuring compliance with regulations. The board's structure and the voting rights associated with shares are designed to maintain a balance between the interests of management, major shareholders, and other stakeholders. Information on the board's composition and any significant changes can be found in the company's public disclosures.

The voting power within SD BioSensor generally follows a one-share-one-vote principle for common shares. This means that voting rights are proportional to share ownership. Details on any special voting rights, founder shares, or dual-class shares, if they exist, would be outlined in the company's articles of incorporation and public disclosures. As of recent reports, there have been no major proxy battles or significant governance controversies that have reshaped decision-making within SD BioSensor.

Key Takeaways on SD BioSensor Ownership

Understanding the board of directors and voting power is crucial for investors and stakeholders of SD BioSensor.

• The board oversees strategic decisions and ensures good governance.
• Voting rights are typically proportional to share ownership.
• Details on board members and voting structures are found in annual reports and public filings.
• No major governance controversies have been reported recently.

SD BioSensor Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership structure of SD BioSensor has seen significant developments. A key event was the acquisition of Meridian Bioscience, Inc. in September 2022, valued at approximately $1.53 billion. This strategic move aimed to broaden SD BioSensor's product offerings and strengthen its global presence, particularly in the U.S. market. Such large acquisitions often influence ownership dynamics through potential share issuances or capital reallocation, which can affect investor sentiment and share prices. The in-vitro diagnostics market is experiencing consolidation, with companies like SD BioSensor actively participating to increase market share and diversify their portfolios.

While specific details on share buybacks or secondary offerings aren't widely publicized, strategic investments and mergers remain key drivers of ownership evolution. The focus on global expansion and product line diversification suggests a continued effort to enhance shareholder value, potentially attracting further institutional investment or leading to future strategic partnerships. The company's efforts to expand its global reach and product lines indicate a focus on enhancing shareholder value, which could draw further institutional investment or lead to future strategic partnerships. For more insights into the company's growth strategy, you can read about the Growth Strategy of SD BioSensor.

Key Development

The acquisition of Meridian Bioscience, Inc. in 2022 significantly impacted SD BioSensor's ownership profile. This strategic move aimed to broaden the company's product portfolio and global presence. The acquisition was valued at approximately $1.53 billion.

Industry Trend

The in-vitro diagnostics market is witnessing consolidation. Companies like SD BioSensor are actively involved in this trend. The goal is to gain market share and diversify product offerings within the industry.

SD BioSensor Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs